Local News

• The CYPHER(R) Stent outperforms the Taxus(R) Stent in people with diabetes  In patients with diabetes, the CYPHER(R) Sirolimus-eluting Coronary Stent outperformed the Taxus(R) Stent with lower rates of in-segment restenosis, target lesion revascularization and major adverse events at nine months according to clinical data.
  Johnson & Johnson August 28, 2008  
• Monsanto and Evogene collaborate on yield and stress research  Monsanto Company and Evogene have entered into a five-year research and development collaboration focused on identifying key plant genes related to yield, environmental stress and fertilizer utilization.
  Monsanto Company August 28, 2008  
• Maxygen receives $3.4 million government grant to develop vaccine discovery technology  Maxygen announced that it has been awarded a 2-year, $3.4 million grant from the United States Department of Defense to develop technology to advance vaccine research and development.
  Maxygen, Inc. August 27, 2008  
• Cytokinetics announces completion of interim safety analysis in ongoing Phase IIa  Cytokinetics announced the completion of a protocol-defined interim analysis in an ongoing Phase IIa clinical trial evaluating the safety of CK-1827452 in patients with ischemic cardiomyopathy and angina.
  Cytokinetics, Incorporated August 27, 2008  
• Amgen alters anemia drug discounts  Amgen is halting some pricing practices that critics say were contributing to overuse of its flagship anemia drug Aranesp at a time of mounting concerns about the product's safety.
  The New York Times August 27, 2008  Andrew Pollack
• CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent receives CE Mark approval  Cordis Corporation announced that it has received CE mark approval to market the CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent for the treatment of acute myocardial infarction (AMI), more commonly known as a heart attack.
  Johnson & Johnson August 27, 2008  
• Cell Genesys halts VITAL-2 GVAX trial in advanced prostate cancer  Cell Genesys announced that it has terminated VITAL-2, the second of two Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, which compares GVAX immunotherapy in combination with Taxotere(R) (docetaxel) to Taxotere plus prednisone in patients with advanced-stage prostate cancer.
  Cell Genesys, Inc. August 27, 2008  
• Cyntellect to collaborate with the Burnham Institute for Medical Research  Cyntellect and the Burnham Institute for Medical Research announced they have entered into a joint collaboration to develop new applications on Cyntellect's in situ live cell imaging and laser processing product (called LEAP(TM)) to accelerate research by Burnham's scientists.
  Cyntellect August 26, 2008  
• Amylin Pharmaceuticals and Eli Lilly provide context for FDA alert for BYETTA  Amylin Pharmaceuticals and Eli Lilly and Company in a conference call provided context and additional information regarding the August 18, 2008 U.S. Food and Drug Administration (FDA) update to a prior alert for BYETTA(R) (exenatide) injection referencing pancreatitis.
  Amylin Pharmaceuticals, Inc. August 26, 2008  
• Bristol-Myers Squibb and Pfizer provide update on apixaban clinical development program  Bristol-Myers Squibb Company and Pfizer provided an update on the apixaban clinical development program. The companies announced that new Phase II data in acute coronary syndrome patients (ACS) will be presented at the upcoming meeting of the European Society of Cardiology (ESC).
  Pfizer Inc. August 26, 2008  

   (next 10 articles)